M-A | Adverse events related to tirzepatide (a dual GIP/GLP-1 receptor agonist)

Adverse Events Related to Tirzepatide – Journal of the Endocrine Society

Related:

RCT | Safety and efficacy of Tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan.

Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis – Diabetologia

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)